美国医疗保健中的药品：数量与价格的决定因素 - Suppr

Suppr

超能文献

Pharmaceuticals in U.S. health care: determinants of quantity and price.

作者信息

Berndt Ernst R

机构信息

MIT Sloan School of Management, Cambridge, Massachusetts, USA.

出版信息

J Econ Perspect. 2002 Fall;16(4):45-66. doi: 10.1257/089533002320950975.

DOI:10.1257/089533002320950975

PMID:15179978

Abstract

摘要

相似文献

Pharmaceuticals in U.S. health care: determinants of quantity and price.

J Econ Perspect. 2002 Fall;16(4):45-66. doi: 10.1257/089533002320950975.

Pharmaceutical expenditure in Sweden.

Health Policy. 1999 May;47(2):125-44. doi: 10.1016/s0168-8510(99)00016-0.

Will lower drug prices jeopardize drug research? A policy fact sheet.

Am J Bioeth. 2004 Winter;4(1):W1-4. doi: 10.1162/152651604773067488.

Increases in Drug Spending Slow.

State Legis. 2017 Apr;43(4):6.

Proposal To Use VA Price As a Benchmark Is off the Mark.

Manag Care. 2016 Dec;25(12):14-15.

Projecting future drug expenditures--1998.

Am J Health Syst Pharm. 1998 Jan 15;55(2):127-36. doi: 10.1093/ajhp/55.2.127.

Rising drug prices drive US manufacturers' revenues, analysis finds.

BMJ. 2015 Oct 7;351:h5376. doi: 10.1136/bmj.h5376.

The drug budget silo mentality: the French case.

Value Health. 2003 Jul-Aug;6 Suppl 1:S10-9. doi: 10.1046/j.1524-4733.6.s1.2.x.

National trends in prescription drug expenditures and projections for 2021.

Am J Health Syst Pharm. 2021 Jul 9;78(14):1294-1308. doi: 10.1093/ajhp/zxab160.

Pharmacoeconomics: the new dismal science.

Adm Policy Ment Health. 2004 May;31(5):425-7. doi: 10.1023/b:apih.0000034419.84114.fb.

引用本文的文献

The optimal co-insurance rate for outpatient drug expenses of Iranian health insured based on the data mining method.

Int J Equity Health. 2024 Feb 8;23(1):25. doi: 10.1186/s12939-023-02065-4.

K-means clustering of outpatient prescription claims for health insureds in Iran.

BMC Public Health. 2023 Apr 28;23(1):788. doi: 10.1186/s12889-023-15753-1.

Understanding profit margins of medical providers from prescription drugs: evidence from Taiwan.

Int Health. 2020 Jul 1;12(4):272-280. doi: 10.1093/inthealth/ihz072.

Affordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioning.

J Int AIDS Soc. 2016 Oct 19;19(1):20619. doi: 10.7448/IAS.19.1.20619. eCollection 2016.

The evolution of Taiwan's National Health Insurance drug reimbursement scheme.

Daru. 2015 Feb 10;23(1):15. doi: 10.1186/s40199-014-0080-7.

Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.

Pharmaceut Med. 2008 Mar 1;22(2). doi: 10.1007/BF03256691.

Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study.

Health Policy. 2014 Jun;116(2-3):196-205. doi: 10.1016/j.healthpol.2013.11.005. Epub 2013 Nov 20.

A Prescription for Drug Formulary Evaluation: An Application of Price Indexes.

Forum Health Econ Policy. 2012 Mar 30;15(2). doi: 10.1515/1558-9544.1296.

Assessing different perspectives on the value of a pharmaceutical innovation.

South Med Rev. 2010 Feb;3(1):24-8. Epub 2010 Feb 15.

Generic substitution: micro evidence from register data in Norway.

Eur J Health Econ. 2011 Feb;12(1):49-59. doi: 10.1007/s10198-010-0226-6. Epub 2010 Mar 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Pharmaceuticals in U.S. health care: determinants of quantity and price.

作者信息

Berndt Ernst R

机构信息

MIT Sloan School of Management, Cambridge, Massachusetts, USA.

出版信息

J Econ Perspect. 2002 Fall;16(4):45-66. doi: 10.1257/089533002320950975.

DOI:10.1257/089533002320950975

PMID:15179978

Abstract

摘要

相似文献

Pharmaceuticals in U.S. health care: determinants of quantity and price.

J Econ Perspect. 2002 Fall;16(4):45-66. doi: 10.1257/089533002320950975.

Pharmaceutical expenditure in Sweden.

Health Policy. 1999 May;47(2):125-44. doi: 10.1016/s0168-8510(99)00016-0.

Will lower drug prices jeopardize drug research? A policy fact sheet.

Am J Bioeth. 2004 Winter;4(1):W1-4. doi: 10.1162/152651604773067488.

Increases in Drug Spending Slow.

State Legis. 2017 Apr;43(4):6.

Proposal To Use VA Price As a Benchmark Is off the Mark.

Manag Care. 2016 Dec;25(12):14-15.

Projecting future drug expenditures--1998.

Am J Health Syst Pharm. 1998 Jan 15;55(2):127-36. doi: 10.1093/ajhp/55.2.127.

Rising drug prices drive US manufacturers' revenues, analysis finds.

BMJ. 2015 Oct 7;351:h5376. doi: 10.1136/bmj.h5376.

The drug budget silo mentality: the French case.

Value Health. 2003 Jul-Aug;6 Suppl 1:S10-9. doi: 10.1046/j.1524-4733.6.s1.2.x.

National trends in prescription drug expenditures and projections for 2021.

Am J Health Syst Pharm. 2021 Jul 9;78(14):1294-1308. doi: 10.1093/ajhp/zxab160.

Pharmacoeconomics: the new dismal science.

Adm Policy Ment Health. 2004 May;31(5):425-7. doi: 10.1023/b:apih.0000034419.84114.fb.

引用本文的文献

The optimal co-insurance rate for outpatient drug expenses of Iranian health insured based on the data mining method.

Int J Equity Health. 2024 Feb 8;23(1):25. doi: 10.1186/s12939-023-02065-4.

K-means clustering of outpatient prescription claims for health insureds in Iran.

BMC Public Health. 2023 Apr 28;23(1):788. doi: 10.1186/s12889-023-15753-1.

Understanding profit margins of medical providers from prescription drugs: evidence from Taiwan.

Int Health. 2020 Jul 1;12(4):272-280. doi: 10.1093/inthealth/ihz072.

Affordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioning.

J Int AIDS Soc. 2016 Oct 19;19(1):20619. doi: 10.7448/IAS.19.1.20619. eCollection 2016.

The evolution of Taiwan's National Health Insurance drug reimbursement scheme.

Daru. 2015 Feb 10;23(1):15. doi: 10.1186/s40199-014-0080-7.

Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.

Pharmaceut Med. 2008 Mar 1;22(2). doi: 10.1007/BF03256691.

Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study.

Health Policy. 2014 Jun;116(2-3):196-205. doi: 10.1016/j.healthpol.2013.11.005. Epub 2013 Nov 20.

A Prescription for Drug Formulary Evaluation: An Application of Price Indexes.

Forum Health Econ Policy. 2012 Mar 30;15(2). doi: 10.1515/1558-9544.1296.

Assessing different perspectives on the value of a pharmaceutical innovation.

South Med Rev. 2010 Feb;3(1):24-8. Epub 2010 Feb 15.

Generic substitution: micro evidence from register data in Norway.

Eur J Health Econ. 2011 Feb;12(1):49-59. doi: 10.1007/s10198-010-0226-6. Epub 2010 Mar 6.